| Lynch, Sharon G |
| Recruiting | 3 | 800 | Europe, Canada, Japan, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Recruiting | 3 | 2060 | Europe, Canada, Japan, US, RoW | Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 12/27 | 09/28 | | |
|
NCT05798520: A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) |
|
|
| Recruiting | 2 | 275 | Europe, US, RoW | BIIB091, DRF, Placebo | Biogen | Relapsing Forms of Multiple Sclerosis | 07/25 | 11/26 | | |
| Completed | 1 | 33 | US | ANK-700, Placebo | Anokion SA | Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis | 04/24 | 04/24 | | |
| Pahwa, Rajesh |
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Terminated | 3 | 7 | Europe, US | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 07/23 | 07/23 | | |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Completed | 3 | 522 | Europe, Canada, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 06/24 | 06/24 | | |
| Active, not recruiting | 2/3 | 110 | Europe, US | AMX0035, Placebo | Amylyx Pharmaceuticals Inc. | Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism | 04/26 | 11/29 | | |
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 |
|
|
| Terminated | 2 | 513 | Europe, US, RoW | K0706, placebo | Sun Pharma Advanced Research Company Limited | Early Parkinson Disease | 04/24 | 06/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424 |
|
|
| Active, not recruiting | 2 | 62 | US | CVN424 150 mg, Placebo | Cerevance Beta, Inc. | Parkinson's Disease | 10/24 | 02/25 | | |
LUMA, NCT05348785 / 2021-004849-20: A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy |
|
|
| Recruiting | 2 | 80 | US | ONO-2808, Placebo | Ono Pharmaceutical Co. Ltd | Multiple System Atrophy (MSA) | 08/25 | 08/25 | | |
APPRISE, NCT03741920: Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status |
|
|
| Active, not recruiting | N/A | 231 | US | Personal KinetiGraph™ (PKG™) | Global Kinetics Corporation | Parkinson Disease | 02/21 | 12/24 | | |
NCT05842434: Pilot Study of the Felix System in Patients With Essential Tremor and Parkinson's Tremor |
|
|
| Completed | N/A | 40 | US | Felix | Fasikl Inc. | Essential Tremor, Parkinson Disease | 11/23 | 11/23 | | |
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor |
|
|
| Active, not recruiting | N/A | 126 | US, RoW | Felix NeuroAI Wristband, Sham Device | Fasikl Inc. | Essential Tremor | 11/24 | 11/25 | | |
| Recruiting | N/A | 1000 | Europe, US, RoW | Deep Brain Stimulation (DBS) | Abbott Medical Devices | Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia | 09/29 | 09/30 | | |
| Taylor, Ryan |
| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
| Holzbeierlein, Jeffrey M |
| Recruiting | N/A | 4400 | US | Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Photocure, Catalyst Pharmaceutical Research | Bladder Cancer | 12/28 | 12/28 | | |
| Lakkireddy, Dhanunjaya |
| Completed | N/A | 1878 | Europe, Canada, US, RoW | Amulet Left Atrial Appendage Occluder, WATCHMAN Left Atrial Appendage Closure | Abbott Medical Devices | Stroke | 12/20 | 05/24 | | |
aMAZE, NCT02513797: Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation |
|
|
| Active, not recruiting | N/A | 600 | US | LARIAT + PVI, Left Atrial Appendage ligation + Pulmonary Vein Isolation, Pulmonary Vein Isolation | AtriCure, Inc. | Atrial Fibrillation | 04/21 | 03/22 | | |
| Completed | N/A | 117 | US | Patient Preference Survey | Abbott Medical Devices | Cardiac Rhythm Disorder, Bradycardia, Cardiac Pacemaker Artificial | 06/23 | 06/23 | | |
| Completed | N/A | 82 | US | LARIAT + PVI, LAA + RF PVI, LAA + Cryo PVI | AtriCure, Inc. | Atrial Fibrillation | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 150 | US | Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device | Abbott Medical Devices | Atrial Fibrillation Paroxysmal, Atrial Fibrillation, Persistent, Cardiac Arrhythmia, Ablation | 12/24 | 12/25 | | |
| Active, not recruiting | N/A | 435 | Europe, Canada, US, RoW | Pulsed Field Ablation | Abbott Medical Devices | Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 01/26 | 01/26 | | |
| Recruiting | N/A | 475 | Europe, Canada, US | Amulet™ 2 Left Atrial Appendage (LAA) Occluder | Abbott Medical Devices | Atrial Fibrillation (AF), Stoke | 07/26 | 07/28 | | |
NCT06676072: A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects with PAF: |
|
|
| Recruiting | N/A | 188 | Europe, US | PFA Ablation catheter | Abbott Medical Devices | Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation | 04/26 | 04/26 | | |
| Recruiting | N/A | 2650 | Europe, Canada, Japan, US, RoW | Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Amplatzer Amulet LAA Occluder, Non-Vitamin K Oral Antagonists, NOAC | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 08/27 | 08/30 | | |
| Active, not recruiting | N/A | 92 | Europe, US | Catheter Ablation | Volta Medical | Atrial Fibrillation | 02/25 | 02/25 | | |
| Recruiting | N/A | 142 | Europe, US | AtriCure ISOLATOR Synergy Surgical Ablation System | AtriCure, Inc. | Inappropriate Sinus Tachycardia | 06/26 | 06/27 | | |
| Recruiting | N/A | 500 | Europe, US | AtriCure Commercially Available Devices | AtriCure, Inc. | Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome | 01/27 | 01/27 | | |
| Active, not recruiting | N/A | 610 | US | Left atrial appendage occlusion (LAAO) | Abbott Medical Devices | Atrial Fibrillation, Stroke, Bleeding | 06/27 | 06/27 | | |
COMPANION AI, NCT06056271: Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation |
|
|
| Recruiting | N/A | 400 | US | AF Ablation | Volta Medical, Heart Rhythm Clinical and Research Solutions, LLC | Atrial Fibrillation | 12/27 | 12/27 | | |
| Completed | N/A | 973 | US | Non-Interventional | Medtronic Cardiac Rhythm and Heart Failure | Atrial Fibrillation | 01/24 | 01/24 | | |
| Recruiting | N/A | 150 | US | FlexAbility SE Ablation Catheter | Abbott Medical Devices | Ventricular Tachycardia | 08/28 | 11/28 | | |
NCT04431544: AcQMap® US Registry of Procedural and Long-term Clinical Outcomes (Discover-US) |
|
|
| Terminated | N/A | 513 | US | AcQMap System | Acutus Medical | Ablation of Arrhythmia's | 11/23 | 11/23 | | |
| Kambhampati, Suman |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 2 | 95 | Europe, US | Tamibarotene, Venetoclax, Venclexta, Azacitidine, Vidaza | Syros Pharmaceuticals, Syros Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 04/28 | 04/28 | | |
| Active, not recruiting | 1/2 | 277 | Europe, Canada, US, RoW | KPT-8602, Eltanexor, ASTX727, Dexamethasone | Karyopharm Therapeutics Inc, Karyopharm Therapeutics Inc. | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 08/24 | 12/24 | | |
|
| Mirza, Moben |
| Recruiting | N/A | 4400 | US | Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system | Photocure, Catalyst Pharmaceutical Research | Bladder Cancer | 12/28 | 12/28 | | |
| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Active, not recruiting | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 07/25 | | |
| Active, not recruiting | 3 | 590 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 06/25 | | |
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy |
|
|
| Recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 12/24 | 01/27 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Not yet recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
| Not yet recruiting | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA) | 12/25 | 12/26 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Not yet recruiting | 3 | 78 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 08/26 | 08/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 06/25 | 05/26 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 05/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
FORTIFI-HN01, NCT06788990: a Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | US | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center | Injury of Ureter During Surgery (Disorder) | 10/25 | 11/25 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 115 | US | Ranibizumab, RGX-314 Dose 1, Combination Product, RGX-314 Dose 2, RGX-314 Dose 3, Local Steroid, Topical Steroid | AbbVie, AbbVie | Neovascular Age-Related Macular Degeneration (nAMD) | 10/25 | 08/26 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Recruiting | 2 | 40 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
| Recruiting | 2 | 32 | RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 06/25 | 10/25 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo |
|
|
| Recruiting | 2 | 120 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 08/25 | 01/26 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Not yet recruiting | 2 | 200 | Japan, US | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Recruiting | 2 | 240 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients with Epidermolysis Bullosa, -study |
|
|
| Not yet recruiting | 2 | 26 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB) | 06/26 | 06/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
| Recruiting | 1/2 | 55 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 03/25 | 09/26 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Active, not recruiting | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Active, not recruiting | 1/2 | 190 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 12/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Recruiting | 1/2 | 145 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 08/24 | 07/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) | 03/25 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) |
|
|
| Not yet recruiting | 1 | 56 | US | SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control | South Rampart Pharma, LLC | Pain | 12/25 | 03/26 | | |
NCT05583669: A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 24 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 05/23 | 05/23 | | |
NCT05633745: A Study to Assess NEU-723 in Healthy Participants |
|
|
| Terminated | 1 | 40 | RoW | NEU-723, Placebo | Neuron23 Inc. | Healthy | 06/23 | 06/23 | | |
| Recruiting | 1 | 85 | Europe, US | DS-9606a | Daiichi Sankyo | Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor | 02/26 | 02/26 | | |
